IMPORTANT SAFETY INFORMATION
OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% must be added to irrigation solution
prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure of phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to
acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory
drugs (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at 2-24% are eye irritation, posterior
capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Use of OMIDRIA in children has not been established.
INDICATIONS AND USAGE
OMIDRIA is added to ophthalmic irrigation solution used during cataract surgery or
intraocular lens replacement and is indicated for maintaining pupil size by preventing
intraoperative miosis and reducing postoperative ocular pain.
References: 1. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2015. 2. Osher RH, Ahmed IIK, Demopulos GA. OMS302
(phenylephrine and ketorolac injection) 1%/0.3% to maintain pupil size and to prevent postoperative ocular pain in cataract surgery with
intraocular lens replacement. Expert Rev Ophthalmol. 2015;10(2):91-103. 3. Hovanesian JA, Sheppard JD, Trattler WB, et al. Intracameral
phenylephrine and ketorolac during cataract surgery to maintain intraoperative mydriasis and reduce postoperative ocular pain: integrated
results from 2 pivotal phase 3 studies. J Cataract Refract Surg. 2015;41(10):2060-2068. 4. Omeros data on file.
Please see the Full Prescribing Information at www.omidria.com/prescribinginformation.
OMEROS®, the OMEROS logo®, OMIDRIA®, and the OMIDRIA logo® are registered
trademarks and OMIDRIAssure
TM
is a trademark of Omeros Corporation.
© Omeros Corporation 2016, all rights reserved. 2016-083
